Cornerstone Therapeutics Inc. (CRTX) Management Discusses Q2 2013 Results (Webcast)

Cornerstone Therapeutics (CRTX): Q2 EPS of $0.33. Revenue of $40.4M beats by $4.61M. (PR)

The following audio is from an earnings conference call that will begin on August 6, 2013, at 8:30 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion.